UK MHRA Aims To Cast Early Access Scheme In New Light
Agency Wants To Make EAMS More Attractive To Sponsors Of Innovative Medicines
Executive Summary
The UK’s Early Access to Medicines Scheme continues to provide important flexibility, but companies also now have the option of a new ambitious pathway launched this year for accelerating time to market for innovative medicines.